ICPO Foundation geht eine Partnerschaft mit der International Atomic Energy Agency (IAEA) ein: Najat Mokhtar, IAEA Deputy Director General and Head of
ICPO Foundation geht eine Partnerschaft mit der International Atomic Energy Agency (IAEA) ein
October 10, 2024 04:15 ET | ICPO Foundation
Die Parteien kooperieren weltweit im Bereich der therapeutischen klinischen Anwendungen der Nuklearmedizin in der Onkologie. 10. Oktober 2024 – Wiesbaden, Deutschland. Heute kündigte die...
ICPO Foundation partners with the International Atomic Energy Agency (IAEA)
ICPO Foundation partners with the International Atomic Energy Agency (IAEA)
October 10, 2024 04:15 ET | ICPO Foundation
The parties cooperate in the area of therapeutic clinical applications of nuclear medicine in oncology worldwide. October 10, 2024 – Wiesbaden, Germany. Today, the International Centers for...
unnamed - 2024-10-08T085210.916
ENCER Now Available on Amazon: A Game-Changer in Relief from Fatigue Related to Cancer Treatment
October 08, 2024 16:29 ET | ENCER
Dr. Yakov Freed, developer of ENCER Photo credit: ENCER DOVER, Del., Oct. 08, 2024 (GLOBE NEWSWIRE) -- ENCER, the groundbreaking homeopathic remedy designed to provide relief from fatigue...
GMILogo_Vertical-Gradient.png
Immune Checkpoint Inhibitors Market to hit USD 189.1 billion by 2032, says Global Market Insights Inc.
October 01, 2024 05:30 ET | Global Market Insights Inc.
Selbyville, Delaware, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Immune Checkpoint Inhibitors Market size reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032...
Michael Chancellor
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
September 25, 2024 08:30 ET | PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
September 24, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
DMR Logo.png
Antibody Drug Conjugates Market Is Expected To Reach Revenue Of USD 51.2 Bn By 2033, at 15.8% CAGR: Dimension Market Research
September 05, 2024 11:45 ET | Dimension Market Research
New York, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Overview The Global Antibody Drug Conjugates (ADCs) Market is projected to grow from USD 13.7 billion in 2024 to USD 51.2 billion by 2033, at a CAGR...
shph logo wire.jpg
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
September 05, 2024 09:00 ET | Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients...
shph logo wire.jpg
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
September 04, 2024 16:15 ET | Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Radiance BioPharma sponsoring Investor Cruise Event 2024
August 29, 2024 15:30 ET | Radiance BioPharma
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...